NRXP vs SGE.L
NRXP: Clinical-stage biotech developing ketamine and NMDA receptor-modulating drugs for treatment-resistant depression, PTSD, and suicidal ideation with three candidates in late-stage FDA review. SGE.L: Sage provides cloud-native financial, HR, and payroll software solutions tailored to the needs of small and medium-sized enterprises globally.
Side-by-side fundamentals
| Metric | NRXP | SGE.L | Edge |
|---|---|---|---|
| Price as of 2026-08-26 close | $3.46 | £11.05 | |
| Market cap as of 2026-08-27 | $150M | $13.3B | |
| Net margin as of 2026-08-27 | -2336.5% | n/a | |
| Gross margin as of 2026-08-27 | +58.8% | n/a | |
| Operating margin as of 2026-08-27 | -1830.6% | n/a | |
| ROE as of 2026-08-27 | -195.8% | n/a | |
| ROA as of 2026-08-27 | -219.6% | n/a | |
| Debt / equity as of 2026-08-27 | 1.42 | n/a | |
| Beta as of 2026-08-27 | 2.05 | n/a | |
| 1-year return as of 2026-08-26 close | +31.6% | +0.4% | NRXP higher |
Fundamentals: market data, as of 2026-08-27. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-26.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.